Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial

The oncologist

article

Véronique Diéras¹  Ave Mori²  Hope S. Rugo³  Richard S. Finn⁴  Nadia Harbeck⁵  Anil Abraham Joy⁶  Karen Gelmon⁷  Johannes Ettl⁸  Sunil Verma⁹  Dongrui R. Lu^1,10  Eric Gauthier^1,10  Patrick Schnell^1,10 

[1] Department of Medical Oncology, Centre Eugène Marquis;Pfizer s.r.l.;University of California San Francisco Helen Diller Family Comprehensive Cancer Center;David Geffen School of Medicine at UCLA;Brustzentrum der Universität München;Cross Cancer Institute, University of Alberta;British Columbia Cancer Agency;Technische Universität;University of Calgary;Pfizer Inc.

关键词: Breast cancer;    Hematologic;    Neutropenia;    Palbociclib;    Safety;   

DOI  :  10.1634/theoncologist.2019-0019

学科分类：地质学

来源: AlphaMed Press Incorporated

【 摘 要 】

Background PALOMA-2 confirmed that first-line palbociclib + letrozole improved progression-free survival (hazard ratio, 0.58; 95% confidence interval, 0.46–0.72) in postmenopausal women with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC). This analysis evaluated palbociclib-associated hematologic adverse events (AEs) and provides insight on managing these AEs. Materials and Methods Postmenopausal women with ER+/HER2− ABC were randomly assigned 2:1 to letrozole (2.5 mg daily continuously) plus oral palbociclib (125 mg daily; 3 weeks on/1 week off) or placebo. Safety assessments were performed at baseline, days 1 and 15 (first two cycles) and day 1 of subsequent cycles, and included white blood cell, platelet, and absolute neutrophil count (ANC). Results PALOMA-2 randomized 666 women to palbociclib + letrozole ( n = 444) or placebo + letrozole (n = 222). Neutropenia was the most common AE (95.3%) with palbociclib (grade 3, 55.6%; grade 4, 11.5%) and was managed by dose modifications; progression-free survival was similar between patients who experienced grade ≥ 3 neutropenia versus those who did not. Median (range) time to onset of neutropenia with palbociclib + letrozole was 15 (12–700) days (grade ≥ 3, 28.0 [12–854] days); median duration of each neutropenia episode grade ≥ 3 was 7.0 days. Asian ethnicity and low baseline ANC were associated with increased risk of grade 3/4 neutropenia with palbociclib ( p < .001). Conclusion Palbociclib + letrozole was generally well tolerated. Neutropenia, the most frequently reported AE in women with ER+/HER2− ABC, was mostly transient and manageable by dose modifications in patients who experienced grade ≥ 3 neutropenia, without appearing to compromise efficacy. (Pfizer; NCT01740427) Implications for Practice Palbociclib demonstrated an acceptable safety profile in PALOMA-2 in women with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC) receiving first-line palbociclib + letrozole. Although hematologic adverse events (AEs) are typically expected with anticancer therapies and are often clinically significant, palbociclib-related hematologic AEs, particularly neutropenia (most frequent AE), were transient/manageable by dose reduction, interruption, or cycle delay, which is in contrast to the more profound neutropenia associated with chemotherapy. Palbociclib dose adjustments decreased hematologic AE severity without appearing to compromise efficacy, supporting palbociclib + letrozole as a first-line treatment for ER+/HER2− ABC.

【 授权许可】

CC BY|CC BY-NC